证券代码：000766 证券简称：通化金马 公告编号：2025-29 通化金马药业集团股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无否决提案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召开时间： 现场会议召开时间为：2025年6月23日下午14:30 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年6月23日9:15—9:25，9:30—11:30和13:00—15:00；通过互联网投票系统 进行网络投票的具体时间为2025年6月23日上午9:15至下午15:00期间的任意时 间。 2、召开地点：吉林省通化市二道江区金马路999号，公司七楼会议室。 3、召开方式：采用现场表决与网络投票相结合的方式召开 4、召集人：公司董事会 5、现场会议主持人：董事长张玉富先生 6、会议召开的合法、合规性：本次会议的召集、召开与表决程序符合《公 司法》《上市公司股东会规则》《深圳证券交易所股票上市规则》等有关法律、行 政法 ...

吉林秉责律师事务所 关于通化金马药业集团股份有限公司 二 0 二四年年度股东大会的法律意见书 致：通化金马药业集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）和《通化金马药业集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，吉林秉责律师事务所（以下简称"本所"）接受了通化金马药业集 团股份有限公司（以下简称"公司"）的委托，担任公司 2024 年年度股东大会（以 下简称"本次股东大会"）特聘专项法律顾问并出具法律意见书。 本法律意见书仅供公司为本次股东大会之目的而使用，不得用于其他任何目 的。本所同意公司将本法律意见书作为本次股东大会的公告材料，随其他需要公 告的信息一起向公众披露，并依法对本所在其中发表的法律意见承担责任。 为出具本法律意见书，本所指派郭淑芬、王红律师出席了公司于 2025 年 6 月 23 日下午 14 点 30 分在公司七楼会议室召开的本次股东大会，审查了公司提 供的召开本次股东大会有关的文件和资料，并进行了验证。在此基础上，本所按 照律师行 ...

Market Overview - The A-share market experienced a downward trend, with major indices closing in the red. The Shanghai Composite Index fell by 0.86%, the Shenzhen Component Index decreased by 1.01%, and the ChiNext Index dropped by 1.1% [2][3]. - The total trading volume in the market reached 805.88 billion CNY, showing a slight increase compared to the previous day [6]. Sector Performance - Energy equipment, semiconductors, banks, and food and beverage sectors showed relative strength, while sectors like defense, multi-finance, textiles, and beauty care struggled [7][19]. - The defense and military industry saw significant declines, with stocks like Guoguang Electric dropping over 10% and several others falling by more than 8% [21][22]. Notable Stocks - In the humanoid robot sector, stocks such as Jiangsu Leili and Shuanglin Shares rose over 10%, with several others hitting the daily limit [12][13]. - Oil and gas stocks experienced gains, with Zhuan Oil Shares achieving a five-day limit-up streak and other companies like Baomo Shares and Maohua Shihua also hitting the limit [15][16]. International Market Trends - The Hong Kong market also faced declines, with major indices dropping over 2%. Notable declines were seen in travel-related stocks like Tongcheng Travel, which fell by 9.27% [9][11]. - The new consumption sector in Hong Kong saw a downturn, with stocks like Pop Mart dropping over 5% [26][28]. Investment Insights - Analysts from Everbright Securities expressed a positive outlook on the oil sector due to ongoing geopolitical uncertainties affecting energy security [19]. - Despite the crowded nature of the new consumption sector, there is a belief in its long-term growth potential supported by industry dynamics, policy, and technological innovation [29].

Group 1 - The A-share innovative drug concept experienced a decline in early trading, with Changshan Pharmaceutical rapidly dropping to the daily limit [1] - Hanyu Pharmaceutical fell over 10%, indicating a significant downturn in the sector [1] - Other companies such as Tonghua Golden Horse, Guangsheng Tang, and Shutaishen also followed the downward trend [1]

证券代码：000766 证券简称：通化金马 公告编号：2025-28 通化金马药业集团股份有限公司 针对此次股票异常波动，公司董事会对公司自身情况进行了核查，并询问了 公司控股股东及实际控制人，现就有关情况说明如下： 1、公司前期披露的信息未发现需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、目前公司经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东和实际控制人目前不存在关于本公司的应披露而未披露 的重大事项，或处于筹划阶段的重大事项。 5、股票异常波动期间，公司控股股东、实际控制人不存在买卖公司股票情 况。 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 通化金马药业集团股份有限公司（以下简称"公司"，证券简称：通化金马， 证券代码：000766）股票交易价格连续三个交易日（2025 年 6 月 12 日、6 月 13 日、6 月 16 日）日收盘价格涨幅偏离值累计超过 20%。根据深圳证券交易所的有 关规定，该情形属于股票交 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][54]. Core Viewpoints - The report highlights that the AD (Alzheimer's Disease) treatment sector is expected to see significant advancements, with a recommendation to focus on companies like Tonghua Jinma and Dongcheng Pharmaceutical [3][9]. - The report emphasizes the importance of innovation, international expansion, and the aging population as key themes driving the industry forward [22][43]. - The pharmaceutical index has shown a positive performance, with a 1.40% increase from June 9 to June 13, outperforming the CSI 300 index by 1.66% [5][22]. Summary by Sections 1. AD Treatment Developments - The report notes that Alzheimer's Disease (AD) is a major global health challenge, with 51.62 million cases worldwide in 2019, including 13.14 million in China [9][10]. - The innovative oral drug, Succinyl-8-hydroxy-aminoguanidine, developed by Tonghua Jinma, has shown promising results in clinical trials and is expected to be a significant player in the AD treatment market [5][21]. 2. Industry Perspectives - The report indicates that the pharmaceutical sector is transitioning from traditional growth drivers to innovative solutions, with a focus on domestic innovation and international market expansion [22][43]. - The aging population is driving demand for chronic disease treatments, and the report suggests that the healthcare payment system is evolving to support this growth [41][43]. 3. Market Performance - The report provides a detailed analysis of stock performance, noting that 218 stocks increased in value while 263 decreased during the reporting period [5][22]. - Specific stocks such as Yiming Pharmaceutical and Sai Sheng Pharmaceutical have shown significant gains, while others like Renmin Tongtai have experienced notable declines [25][26]. 4. Investment Recommendations - The report recommends focusing on innovative pharmaceutical companies and those with strong international expansion capabilities, such as Heng Rui Pharmaceutical and Keren Pharmaceutical [43][44]. - It also highlights the importance of investing in sectors related to aging and outpatient consumption, suggesting companies like Kunming Pharmaceutical and Yuyue Medical [44].

Group 1 - The Alzheimer's concept sector declined by 0.90%, ranking among the top declines in the concept sector, with notable declines from companies such as Wanbangde, Tonghua Jinma, and Kanghong Pharmaceutical [1][2] - Among the stocks in the Alzheimer's concept sector, 9 stocks experienced price increases, with Beilu Pharmaceutical, Lisheng Pharmaceutical, and Haizheng Pharmaceutical leading the gains at 4.42%, 3.36%, and 1.77% respectively [1][2] - The Alzheimer's concept sector saw a net outflow of 408 million yuan from major funds, with 22 stocks experiencing net outflows, and 5 stocks seeing outflows exceeding 30 million yuan, led by Tonghua Jinma with a net outflow of 126 million yuan [2][3] Group 2 - The top net inflow stocks in the Alzheimer's concept sector included Beilu Pharmaceutical, Luhua Pharmaceutical, and Meinian Health, with net inflows of 23.6 million yuan, 14.7 million yuan, and 14.2 million yuan respectively [2][3] - The stocks with the highest net outflows in the Alzheimer's concept sector included Tonghua Jinma, Changchun Gaoxin, and Dian Diagnostics, with net outflows of 125.8 million yuan, 53.6 million yuan, and 51.5 million yuan respectively [2][3] - The trading activity in the Alzheimer's concept sector showed significant turnover rates, with stocks like Tonghua Jinma and Wanbangde having turnover rates of 4.80% and 15.18% respectively [2][3]

Group 1 - The A-share chemical pharmaceutical sector is experiencing a volatile correction, with companies such as Haichen Pharmaceutical and Yong'an Pharmaceutical both declining over 9% [1] - Other companies including Yipinhong, Hasanlian, Tonghua Jinma, Hanyu Pharmaceutical, and Hehua Co. have also seen declines of around 5% [1]

通化金马药业集团股份有限公司 《股东大会议事规则》修改对照表 公司第十一届董事会 2025 年第六次临时会议于 2025 年 5 月 30 日召开，会 议审议通过了《关于修改<股东大会议事规则>的议案》，并将《股东大会议事规 则》更名为《股东会议事规则》。《股东大会议事规则》修改对照表如下： | 序号 | 修改前 | 修改后 | | --- | --- | --- | | 1 | 股东大会议事规则 | 股东会议事规则 | | 2 | 全文"股东大会" 第四条 股东大会分为年度股东大会和临时股 | 修改为"股东会" 第四条 股东会分为年度股东会和临时股东会。 | | | 东大会。年度股东大会每年召开一次,应当于 | 年度股东会每年召开一次,应当于上一会计年度 | | | 上一会计年度结束后的 6 个月内举行。临时股 | 结束后的 6 个月内举行。临时股东会不定期召 | | 3 | 东大会不定期召开,出现《公司法》第一百条 | 开,出现《公司法》第一百一十三条规定的应当 | | | 规定的应当召开临时股东大会的情形时,临时 | 召开临时股东会的情形时,临时股东会应当在 2 | | | 股东大会应当在 2 个月内召 ...

第四条 独立董事原则上最多在三家境内上市公司兼任独立董事，并确保有 足够的时间和精力有效地履行独立董事的职责。 通化金马药业集团股份有限公司 独立董事工作制度 （经 2025 年 5 月 30 日公司召开的第十一届董事会 2025 年第六次临时会议审议通过） 第一章 总则 第一条 为完善公司治理结构，切实保护中小股东及利益相关者的合法权益， 促进公司规范运作，根据《公司法》《证券法》《上市公司独立董事管理办法》《上 市公司治理准则》《通化金马药业集团股份有限公司章程》（以下简称"公司章程"） 等相关规定，并结合公司实际，制定本独立董事工作制度。 第二条 公司独立董事是指不在公司担任除独立董事外的任何其他职务，并 与公司及主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影 响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，对公司负有保密 义务。 独立董事应当按照法律、行政法规、中国证券监督管理委员会（以下简 称中国证监会）规定、深圳证券交易所业务规则和公司章程的规定，认真履行职 责， ...